Induced pluripotent stem cells in hematology: Current and future applications

Blood Cancer Journal

Volumn 4, Issue 5, 2014, Pages

  Focosi, D ^a   Amabile, G ^b,c   Di Ruscio, A ^b,c   Quaranta, P ^d   Tenen, D G ^b,e   Pistello, M ^d  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD STEM CELL INSTITUTE   (United States)

^d UNIVERSITY OF PISA   (Italy)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBINOPATHY; HUMAN; IMMUNOGENICITY; NONHUMAN; PLURIPOTENT STEM CELL; REVIEW; SICKLE CELL ANEMIA; STEM CELL TRANSPLANTATION; THALASSEMIA; ANIMAL; CYTOLOGY; HEMATOLOGY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; PHYSIOLOGY; PROCEDURES;

ANIMALS; HEMATOLOGY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INDUCED PLURIPOTENT STEM CELLS;

EID: 84901982591     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2014.30     Document Type: Review

References (84)

1. Amabile G, Meissner A. Induced pluripotent stem cells: current progress and potential for regenerative medicine. Trends Mol Med 2009; 15: 59-68.
2. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-676.
3. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861-872.
4. Yu J, Vodyanik MS-O K, Antosiewicz-Bourget J, Frane J, Tian S, Nie J et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318: 1917-1920.
5. Jincho Y, Araki R, Hoki Y, Tamura C, Nakamura M, Ando S et al. Generation of genome integration-free induced pluripotent stem cells from fibroblasts of C57BL/6 mice without c-Myc transduction. J Biol Chem 2010; 285: 26384-26389.
6. Li HY, Chien Y, Chen YJ, Chen SF, Chang YL, Chiang CH et al. Reprogramming induced pluripotent stem cells in the absence of c-Myc for differentiation into hepatocyte-like cells. Biomaterials 2011; 32: 5994-6005.
7. Chiou S-H, Jiang B-H, Yu Y-L, Chou S-J, Tsai P-H, Chang W-C et al. Poly(ADP-ribose) polymerase 1 regulates nuclear reprogramming and promotes iPSC generation without c-Myc. J Exp Med 2013; 210: 85-98.
8. Doege CA, Inoue K, Yamashita T, Rhee DB, Travis S, Fujita R et al. Early-stage epigenetic modification during somatic cell reprogramming by Parp1 and Tet2. Nature 2012; 488: 652-655.
9. Griscelli F, Feraud O, Oudrhiri N, Gobbo E, Casal I, Chomel JC et al. Malignant germ cell-like tumors, expressing Ki-1 antigen (CD30), are revealed during in vivo differentiation of partially reprogrammed human-induced pluripotent stem cells. Am J Pathol 2012; 180: 2084-2096.
10. Sommer CA, Christodoulou C, Gianotti-Sommer A, Shen SS, Sailaja BS, Hezroni H et al. Residual expression of reprogramming factors affects the transcriptional program and epigenetic signatures of induced pluripotent stem cells. PLoS One 2012; 7: e51711.
11. Sommer CA, Mostoslavsky G. Experimental approaches for the generation of induced pluripotent stem cells. Stem Cell Res Ther 2010; 1: 26.
12. DeKelver RC, Choi VM, Moehle EA, Paschon DE, Hockemeyer D, Meijsing SH et al. Functional genomics, proteomics, and regulatory DNA analysis in isogenic settings using zinc finger nuclease-driven transgenesis into a safe harbor locus in the human genome. Genome Res 2010; 20: 1133-1142.
13. Bayart E, Cohen-Haguenauer O. Technological overview of iPS induction from human adult somatic cells. Curr Gene Ther 2013; 13: 73-92.
14. Zimmermann A, Preynat-Seauve O, Tiercy JM, Krause KH, Villard J. Haplotype-based banking of human pluripotent stem cells for transplantation: potential and limitations. Stem Cells Dev 2012; 21: 2364-2373.
15. Kim EM, Manzar G, Zavazava N. Human iPS cell-derived hematopoietic progenitor cells induce T-cell anergy in in vitro-generated alloreactive CD8() T cells. Blood 2013; 121: 5167-5175.
16. Liu Z, Wen X, Wang H, Zhou J, Zhao M, Lin Q et al. Molecular imaging of induced pluripotent stem cell immunogenicity with in vivo development in ischemic myocardium. PLoS One 2013; 8: e66369.
17. Zhao T, Zhang Z-N, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells. Nature 2011; 474: 212-215.
18. Araki R, Uda M, Hoki Y, Sunayama M, Nakamura M, Ando S et al. Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature 2013; 494: 100-104.
19. Dhodapkar KM, Feldman D, Matthews P, Radfar S, Pickering R, Turkula S et al. Natural immunity to pluripotency antigen OCT4 in humans. Proc Natl Acad Sci USA 2010; 107: 8718-8723.
20. Garcon L, Ge J, Manjunath SH, Mills JA, Apicella M, Parikh S et al. Ribosomal and hematopoietic defects in induced pluripotent stem cells derived from Diamond Blackfan anemia patients. Blood 2013; 122: 912-921.
21. Raya A, Rodriguez-Piza I, Guenechea G, Vassena R, Navarro S, Barrero MJ et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature 2009; 460: 53-59.
22. Kinoshita T, Nagamatsu G, Kosaka T, Takubo K, Hotta A, Ellis J et al. Ataxia-telangiectasia mutated (ATM) deficiency decreases reprogramming efficiency and leads to genomic instability in iPS cells. Biochem Biophys Res Commun 2011; 407: 321-326.
23. Raya A, Rodriguez-Piza I, Navarro S, Richaud-Patin Y, Guenechea G, Sanchez-Danes A et al. A protocol describing the genetic correction of somatic human cells and subsequent generation of iPS cells. Nat Protoc 2010; 5: 647-660.
24. Dong A, Rivella S, Breda L. Gene therapy for hemoglobinopathies: progress and challenges. Transl Res 2013; 161: 293-306.
25. Tubsuwan A, Abed S, Deichmann A, Kardel MD, Bartholoma C, Cheung A et al. Parallel assessment of globin lentiviral transfer in induced pluripotent stem cells and adult hematopoietic stem cells derived from the same transplanted beta-thalassemia patient. Stem Cells 2013; 31: 1785-1794.
26. Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, Fusil F et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 2010; 467: 318-322.
27. Ma N, Liao B, Zhang H, Wang L, Shan Y, Xue Y et al. TALEN-mediated gene correction in integration-free beta-thalassemia iPSCs. J Biol Chem 2013; 288: 34671-34679.
28. Chang CJ, Bouhassira EE. Zinc-finger nuclease-mediated correction of alpha-thalassemia in iPS cells. Blood 2012; 120: 3906-3914.
29. Romero Z, Urbinati F, Geiger S, Cooper AR, Wherley J, Kaufman ML et al. beta-globin gene transfer to human bone marrow for sickle cell disease. J Clin Invest 2013; 1: Pii: 67930.
30. Wu L-C, Sun C-W, Ryan TM, Pawlik KM, Ren J, Townes TM. Correction of sickle cell disease by homologous recombination in embryonic stem cells. Blood 2006; 108: 1183-1188.
31. Hanna J, Wernig M, Markoulaki S, Sun CW, Meissner A, Cassady JP et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 2007; 318: 1920-1923.
32. Zou J, Mali P, Huang X, Dowey SN, Cheng L. Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease. Blood 2011; 118: 4599-4608.
33. Giorgetti A, Montserrat N, Rodriguez-Piza I, Azqueta C, Veiga A, Izpisua Belmonte JC. Generation of induced pluripotent stem cells from human cord blood cells with only two factors: Oct4 and Sox2. Nat Protoc 2010; 5: 811-820.
34. Ohmine S, Dietz AB, Deeds MC, Hartjes KA, Miller DR, Thatava T et al. Induced pluripotent stem cells from GMP-grade hematopoietic progenitor cells and mononuclear myeloid cells. Stem Cell Res Ther 2011; 2: 46.
35. Merling RK, Sweeney CL, Choi U, De Ravin SS, Myers TG, Otaizo-Carrasquero F et al. Transgene-free iPSCs generated from small volume peripheral blood nonmobilized CD34 cells. Blood 2013; 121: e98-107.
36. Gori JL, Chandrasekaran D, Kowalski JP, Adair JE, Beard BC, D'Souza SL et al. Efficient generation, purification, and expansion of CD34() hematopoietic progenitor cells from nonhuman primate-induced pluripotent stem cells. Blood 2012; 120: e35-e44.
37. Slukvin II. Hematopoietic specification from human pluripotent stem cells: current advances and challenges toward de novo generation of hematopoietic stem cells. Blood 2013; 122: 4035-4046.
38. Gao J, Yan XL, Li R, Liu Y, He W, Sun S et al. Characterization of OP9 as authentic mesenchymal stem cell line. J Genet Genomics 2010; 37: 475-482.
39. Woods NB, Parker AS, Moraghebi R, Lutz MK, Firth AL, Brennand KJ et al. Brief report: efficient generation of hematopoietic precursors and progenitors from human pluripotent stem cell lines. Stem Cells 2011; 29: 1158-1164.
40. Kitajima K, Minehata K, Sakimura K, Nakano T, Hara T. In vitro generation of HSC-like cells from murine ESCs/iPSCs by enforced expression of LIM-homeobox transcription factor Lhx2. Blood 2011; 117: 3748-3758.
41. Amabile G, Welner RS, Nombela-Arrieta C, D'Alise AM, Di Ruscio A, Ebralidze AK et al. In vivo generation of transplantable human hematopoietic cells from induced pluripotent stem cells. Blood 2013; 121: 1255-1264.
42. Suzuki N, Yamazaki S, Yamaguchi T, Okabe M, Masaki H, Takaki S et al. Generation of engraftable hematopoietic stem cells from induced pluripotent stem cells by way of teratoma formation. Mol Ther 2013; 21: 1424-1431.
43. Wang L, Li L, Shojaei F, Levac K, Cerdan C, Menendez P et al. Endothelial and hematopoietic cell fate of human embryonic stem cells originates from primitive endothelium with hemangioblastic properties. Immunity 2004; 21: 31-41.
44. Wang L, Menendez P, Shojaei F, Li L, Mazurier F, Dick JE et al. Generation of hematopoietic repopulating cells from human embryonic stem cells independent of ectopic HOXB4 expression. J Exp Med 2005; 201: 1603-1614.
45. Ng ES, Davis RP, Azzola L, Stanley EG, Elefanty AG. Forced aggregation of defined numbers of human embryonic stem cells into embryoid bodies fosters robust, reproducible hematopoietic differentiation. Blood 2005; 106: 1601-1603.
46. Pick M, Azzola L, Mossman A, Stanley EG, Elefanty AG. Differentiation of human embryonic stem cells in serum-free medium reveals distinct roles for bone morphogenetic protein 4, vascular endothelial growth factor, stem cell factor, and fibroblast growth factor 2 in hematopoiesis. Stem Cells 2007; 25: 2206-2214.
47. Ledran MH, Krassowska A, Armstrong L, Dimmick I, Renstrom J, Lang R et al. Efficient hematopoietic differentiation of human embryonic stem cells on stromal cells derived from hematopoietic niches. Cell Stem Cell 2008; 3: 85-98.
48. Wang Y, Yates F, Naveiras O, Ernst P, Daley GQ. Embryonic stem cell-derived hematopoietic stem cells. Proc Natl Acad Sci USA 2005; 102: 19081-19086.
49. Lu M, Kardel MD, O'Connor MD, Eaves CJ. Enhanced generation of hematopoietic cells from human hepatocarcinoma cell-stimulated human embryonic and induced pluripotent stem cells. Exp Hematol 2009; 37: 924-936.
50. Wang N, Rajasekaran N, Hou T, Lisowski L, Mellins ED. Comparison of transduction efficiency among various lentiviruses containing GFP reporter in bone marrow hematopoietic stem cell transplantation. Exp Hematol 2013; 41: 934-943.
51. Joung JK, Sander JD. TALENs: a widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol 2013; 14: 49-55.
52. Eggenschwiler R, Loya K, Wu G, Sharma AD, Sgodda M, Zychlinski D et al. Sustained knockdown of a disease-causing gene in patient-specific induced pluripotent stem cells using lentiviral vector-based gene therapy. Stem Cells Transl Med 2013; 2: 641-654.
53. Sung YH, Kim JM, Kim HT, Lee J, Jeon J, Jin Y et al. Highly efficient gene knockout in mice and zebrafish with RNA-guided endonucleases. Genome Res 2013; 24: 125-131.
54. Zou J, Sweeney CL, Chou BK, Choi U, Pan J, Wang H et al. Oxidase-deficient neutrophils from X-linked chronic granulomatous disease iPS cells: functional correction by zinc finger nuclease-mediated safe harbor targeting. Blood 2011; 117: 5561-5572.
55. Sebastiano V, Maeder ML, Angstman JF, Haddad B, Khayter C, Yeo DT et al. In situ genetic correction of the sickle cell anemia mutation in human induced plur-ipotent stem cells using engineered zinc finger nucleases. Stem Cells 2011; 29: 1717-1726.
56. Sakuma T, Hosoi S, Woltjen K, Suzuki K, Kashiwagi K, Wada H et al. Efficient TALEN construction and evaluation methods for human cell and animal applications. Genes Cells 2013; 18: 315-326.
57. Horii T, Tamura D, Morita S, Kimura M, Hatada I. Generation of an ICF syndrome model by efficient genome editing of human induced pluripotent stem cells using the CRISPR system. Int J Mol Sci 2013; 14: 19774-19781.
58. Hou Z, Zhang Y, Propson NE, Howden SE, Chu LF, Sontheimer EJ et al. Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis. Proc Natl Acad Sci USA 2013; 110: 15644-15649.
59. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE et al. RNA-guided human genome engineering via Cas9. Science 2013; 339: 823-826.
60. Li M, Suzuki K, Kim NY, Liu GH, Izpisua Belmonte JC. A cut above the rest: targeted genome editing technologies in human pluripotent stem cells. J Biol Chem 2013; 289: 4594-4599.
61. Shah S, Huang X, Cheng L. Concise review: stem cell-based approaches to red blood cell production for transfusion. Stem Cells Transl Med 2013; 3: 346-355.
62. Nakagawa Y, Nakamura S, Nakajima M, Endo H, Dohda T, Takayama N et al. Two differential flows in a bioreactor promoted platelet generation from human pluripotent stem cell-derived megakaryocytes. Exp Hematol 2013; 41: 742-748.
63. Wong KL, Yeap WH, Tai JJ, Ong SM, Dang TM, Wong SC. The three human monocyte subsets: implications for health and disease. Immunol Res 2012; 53: 41-57.
64. Matsunaga Y, Fukuma D, Hirata S, Fukushima S, Haruta M, Ikeda T et al. Activation of antigen-specific cytotoxic T lymphocytes by beta 2-microglobulin or TAP1 gene disruption and the introduction of recipient-matched MHC class I gene in allogeneic embryonic stem cell-derived dendritic cells. J Immunol 2008; 181: 6635-6643.
65. Yanagimachi MD, Niwa A, Tanaka T, Honda-Ozaki F, Nishimoto S, Murata Y et al. Robust and highly-efficient differentiation of functional monocytic cells from human pluripotent stem cells under serum-and feeder cell-free conditions. PLoS One 2013; 8: e59243.
66. Silk KM, Silk JD, Ichiryu N, Davies TJ, Nolan KF, Leishman AJ et al. Cross-presentation of tumour antigens by human induced pluripotent stem cell-derived CD141()XCR1 dendritic cells. Gene Ther 2012; 19: 1035-1040.
67. Haruta M, Tomita Y, Yuno A, Matsumura K, Ikeda T, Takamatsu K et al. TAP-deficient human iPS cell-derived myeloid cell lines as unlimited cell source for dendritic cell-like antigen-presenting cells. Gene Ther 2013; 20: 504-513.
68. Vogel B, Tennert K, Full F, Ensser A. Efficient generation of human natural killer cell lines by viral transformation. Leukemia 2014; 28: 192-195.
69. Knorr DA, Ni Z, Hermanson D, Hexum MK, Bendzick L, Cooper LJ et al. Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy. Stem Cells Transl Med 2013; 20: 274-283.
70. Ni Z, Knorr DA, Clouser CL, Hexum MK, Southern P, Mansky LM et al. Human pluripotent stem cells produce natural killer cells that mediate anti-HIV-1 activity by utilizing diverse cellular mechanisms. J Virol 2011; 85: 43-50.
71. Vizcardo R, Masuda KY, D, Ikawa TS, Fujii SK K, HKawamoto H. Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8() T cells. Cell Stem Cell 2013; 12: 31-36.
72. Themeli M, Kloss CC, Ciriello G, Fedorov VD, Perna F, Gonen M et al. Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat Biotechnol 2013; 31: 928-933.
73. Nishimura T, Kaneko S, Kawana-Tachikawa A, Tajima Y, Goto H, Zhu DN-H et al. Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation. Cell Stem Cell 2013; 12: 114-126.
74. Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 2013; 122: 863-871.
75. Watarai H, Yamada D, Fujii S, Taniguchi M, Koseki H. Induced pluripotency as a potential path towards iNKT cell-mediated cancer immunotherapy. Int J Hematol 2012; 95: 624-631.
76. Wakao H, Yoshikiyo K, Koshimizu U, Furukawa T, Enomoto K, Matsunaga T et al. Expansion of functional human mucosal-associated invariant T cells via reprogramming to pluripotency and redifferentiation. Cell Stem Cell 2013; 12: 546-558.
77. Carpenter L, Malladi R, Yang CT, French A, Pilkington KJ, Forsey RW et al. Human induced pluripotent stem cells are capable of B-cell lymphopoiesis. Blood 2011; 117: 4008-4011.
78. Rajesh D, Dickerson SJ, Yu J, Brown ME, Thomson JA, Seay NJ. Human lympho-blastoid B-cell lines reprogrammed to EBV-free induced pluripotent stem cells. Blood 2011; 118: 1797-1800.
79. Ge X, Wang IN, Toma I, Sebastiano V, Liu J, Butte MJ et al. Human amniotic mesenchymal stem cell-derived induced pluripotent stem cells may generate a universal source of cardiac cells. Stem Cells Dev 2012; 21: 2798-2808.
80. Moslem M, Valojerdi MR, Pournasr B, Muhammadnejad A, Baharvand H. Therapeutic potential of human induced pluripotent stem cell-derived mesenchymal stem cells in mice with lethal fulminant hepatic failure. Cell Transplant 2013; 22: 1785-1799.
81. Sun YQ, Deng MX, He J, Zeng QX, Wen W, Wong DS et al. Human pluripotent stem cell-derived mesenchymal stem cells prevent allergic airway inflammation in mice. Stem Cells 2012; 30: 2692-2699.
82. Jung Y, Bauer G, Nolta JA. Concise review: Induced pluripotent stem cell-derived mesenchymal stem cells: progress toward safe clinical products. Stem Cells 2012; 30: 42-47
83. Razvi E. iPSC quantitative market opportunity. GENReports: Market & Tech Analysis 2014. Available from http://www.genengnews.com/media/pdf/GEN- Biomarket-Trends-Report-iPSC-Market-Opportunity.pdf.
84. Nielen MG, de Vries SA, Geijsen N. European stem cell research in legal shackles. EMBO J 2013; 32: 3107-3111.